Barclays’s Shuttle Pharmaceuticals SHPH Stock Holding History

Barclays’s Portfolio SHPH Stock Details SHPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Hold	0	–	-$1	–	5511
2025 Q1	–	Hold	0	–	–	–	5232
2022 Q4	–	Sell	-4	Closed	-$39K	–	5359
2022 Q3	$39K	Buy	+4	New	+$163K	﹤0.01%	3856

Other funds holding SHPH

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Barclays's SHPH Position: Q2 2025 in Review

Barclays held its Shuttle Pharmaceuticals (SHPH) position steady in Q2 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5511.

Barclays first reported a position in SHPH in Q3 2022 and has held it in 1 quarter since. The position peaked at $39K in Q3 2022. 3 funds tracked by Wall St. Rank hold SHPH as of Q2 2025.

Barclays held 0 shares of Shuttle Pharmaceuticals worth $0 as of Q2 2025.
Barclays left its Shuttle Pharmaceuticals share count unchanged in Q2 2025.
Shuttle Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2025, its #5511 holding.
Barclays first reported a position in Shuttle Pharmaceuticals in Q3 2022 and has held it in 1 quarter since.
Barclays's Shuttle Pharmaceuticals position peaked at $39K in Q3 2022.
3 funds tracked by Wall St. Rank held Shuttle Pharmaceuticals as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.